Hokkaido Phase II Study of Photo-Immunotherapy Combination with ASP-1929 for Radio-resistant Recurrent or Persistent vulvar, vaginal lesions with EGFR-positive gynecologic cancers (HICARi study)
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Cetuximab sarotalocan (Primary) ; Antihistamines; Corticosteroids
- Indications Cervical cancer; Gynaecological cancer
- Focus Therapeutic Use
- Acronyms HICARi study
- 03 Feb 2025 New trial record